Sunesis, Inovio planning follow-ons
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) and Inovio Pharmaceuticals Inc. (NYSE-M:INO) both proposed follow-ons after market close on Wednesday. Cowen and Cantor Fitzgerald are underwriters of Sunesis' offering. The company's vosaroxin ( AG-7352) is in the Phase III VALOR trial for relapsed or refractory acute myelogenous leukemia (AML). Sunesis has exclusive, worldwide rights to develop and commercialize the quinolone derivative that intercalates DNA and inhibits topoisomerase II (TOP2) from Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506).
Piper Jaffray and Stifel are underwriters of Inovio's follow-on. The company's VGX-3100, a DNA-based therapeutic vaccine targeting the E6 and E7 proteins of HPV 16 and 18, is in Phase II testing to treat cervical intraepithelial neoplasia (CIN) caused by HPV types 16 and 18. ...